Abstract
Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tumor biology and cancer therapy – an evolving relationship
Cell Communication and Signaling Open Access 13 August 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Diaz-Rubio E et al. (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224–4230
Porschen R et al. (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217–4223
Cassidy J et al. (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006–2012
Saltz LB et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013–2019
Haller DG et al. (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26: 2118–2123
Hochster HS et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523–3529
Schmoll HJ et al. (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25: 102–109
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author is a Consultant for Genentech, Roche and Sanofi-Aventis. He receives grant/research support from Genentech and Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Grothey, A. A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. Nat Rev Clin Oncol 6, 10–11 (2009). https://doi.org/10.1038/ncponc1261
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1261
This article is cited by
-
Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer
Strahlentherapie und Onkologie (2014)
-
Tumor biology and cancer therapy – an evolving relationship
Cell Communication and Signaling (2009)
